Longeveron Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 45.4K | $47.20K | 0.00% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 752 | $782 | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.19 | — | — |
| 2026-05-13 | -0.17 | -0.19 | -10.14% |
| 2026-03-17 | -0.37 | -0.22 | +40.00% |
| 2025-11-04 | -0.26 | -0.39 | -51.95% |
| 2025-08-13 | -0.35 | -0.33 | +6.38% |
| 2025-05-08 | -0.33 | -0.34 | -3.82% |
| 2024-11-12 | -0.44 | -0.34 | +23.31% |
| 2024-08-14 | -0.87 | -1.83 | -110.34% |
| 2024-05-14 | -2.00 | -1.61 | +19.70% |
| 2024-02-27 | -2.05 | -2.50 | -21.95% |
| 2023-11-09 | -2.40 | -2.80 | -16.67% |
| 2023-08-11 | -2.47 | -2.70 | -9.46% |
| 2023-05-12 | -2.25 | -2.20 | +2.22% |
| 2023-03-10 | -2.00 | -2.10 | -5.00% |
| 2022-11-14 | -2.20 | -2.50 | -13.64% |
| 2022-08-12 | -2.27 | -2.70 | -19.12% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LGVN | -9.28% | +38.35% | +52.57% | -37.74% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -12.25% | +42.99% | +56.01% | -50.43% |